The latest reminder of Big Pharma’s influence over the American healthcare sector did not come from a footnote in a medical journal, but from Washington trade policy. In July 2026, POLITICO reported pharmaceutical companies were aggressively lobbying US trade officials to open tariff investigations into European countries with tightly controlled medicine prices. The strategy was not simply to tax medicines at the border. It was to use the threat of trade barriers to force governments into talks that could ultimately push prices higher.
This case demonstrates the scale of influence major US pharmaceutical companies have over the industry in its most concrete form. The same industry that funds research, pays consultants and sponsors medical writing, also spent more than $4.4 billion lobbying Washington, between 2018 and 2025, to shape the rules around pricing, access and regulation.
Conflicts of interest in the pharmaceutical industry are not just about who paid for a study or who sat on whose board. They exist through three main channels: academic sponsorship, lobbying, and payments or perks to medical professionals. These three routes of influence can shape which drugs are researched, how evidence is framed, which treatments doctors hear most about, and what patients are asked to pay, with direct consequences for healthcare outcomes for millions of Americans every year.
How Pharmaceutical Industry Funding Influences Clinical Research
Corporate money has an obvious place in academic research. Medical studies are expensive, and many would not happen without pharmaceutical funding. That does not make these relationships harmless.
Research suggests that who pays for a study can influence what it ultimately finds. One study found that manufacturer-sponsored trials reported drugs as 49% more effective when compared to trials of the same drug without sponsorship, while a 2024 analysis found that 58.9% of physician peer reviewers at The BMJ, JAMA, The Lancet and NEJM had received industry payments, totalling more than $1 billion.
Such findings are concerning, because the commercial stakes attached to clinical research can be enormous. AstraZeneca offered a particularly stark example this year. In July, its shares fell by nearly 10% after Wainua, a gene-silencing treatment for ATTR-CM, failed to meet the primary endpoint in a Phase III trial. To be clear, this result does not suggest anything improper about the trial. It shows the enormous costs of poor clinical trial data, and why questions about corporate funding matter when so much value can hinge on the evidence doctors, regulators and patients rely on.
How Pfizer Lobbying Influences Drug Pricing Policy
Pharmaceutical lobbying is growing steeply. Spending in the sector grew from $386 million in 2024 to $456 million in 2025, the largest single-year increase on record, according to data from OpenSecrets. Pfizer is one case study of a company that encapsulates the entire pharmaceutical industry.
The company has had notable access to the Trump administration. It contributed $1 million to Trump’s 2017 and 2025 inaugurations, with CEO Albert Bourla attending Trump’s 2025 inauguration, and has remained closely engaged with the administration.
In Q4 2025 alone, Pfizer disclosed $1.72 million in lobbying, some of which went towards issues being actively debated by the Trump administration and Congress, including PBM reform, Medicare and Medicaid drug-pricing policy, and legislation connected to orphan-drug rules.
The more important point is what this level of access can coincide with. In September 2025, Pfizer became the first major drugmaker to strike a pricing agreement under the administration’s most-favored-nation-pricing initiative, setting the benchmark for the companies that followed.
Bourla later publicly thanked Trump for his “friendship” while announcing a drug-pricing agreement at the White House.
In return for commitments on drug pricing and US investment, Pfizer received a three-year reprieve from proposed pharmaceutical tariffs. While there is no tangible basis for claiming that lobbying or political access created that outcome, Pfizer’s position shows how proximity to the levers of power can pay dividends for the world’s major pharmaceutical companies.
How Pharmaceutical Payments to Doctors Can Influence Prescribing
The problem is not only individual bad actors, but also the incentive structure around blockbuster drugs, market share and prescribing behaviour. When companies are rewarded for expanding use as quickly as possible, the line between legitimate support and paying for influence can become dangerously easy to blur. In some cases, companies go further and abuse those rules outright for commercial gain.
Veloxis Pharmaceuticals offers one recent example. Earlier in August, the Department of Justice said the company allegedly used financial benefits to influence doctors and pharmacies to prescribe or buy its drug Envarsus.
The company admitted to providing healthcare professionals with expensive meals, alcohol, luxury trips and resort stays. It admitted making consulting payments for work that was not actually performed, effectively disguising inducements. Veloxis employees even allegedly falsified expense reports, including by omitting doctors’ names, to make the spending appear less suspicious. Eventually, Veloxis agreed to pay more than $46 million to resolve the case.
The more troubling question is what the system allowed before that point. If financial incentives can shape prescribing choices for years before enforcement catches up, patients may never know whether a medicine was recommended because it was best for them, or because the system around it was quietly pushing in that direction.
These conflicts of interest also have global consequences, particularly in the Global South, where weaker health systems, limited regulatory capacity and dependence on imported medicines can make countries more vulnerable to the influence of multinational pharmaceutical companies. Nigeria offers a useful example. As one of Africa’s largest pharmaceutical markets, it relies heavily on imported medicines while facing persistent challenges around affordability, access and regulation.
Ultimately, this is not an abstract debate about disclosure forms, lobbying reports or settlement figures. It is about the healthcare decisions that shape people’s lives, and about whether the interests of ordinary Americans are being put ahead of the companies that so easily run in the same circles as elected decision makers.
Ure Utah is a Nigerian-American public affairs and sustainable-development strategist whose work sits at the intersection of government, international partnerships and development finance. Founder of Bridge Synergy, she has worked on initiatives designed to connect Nigerian projects with international capital and expertise, including efforts supporting the country’s Sustainable Development Goals and was formerly a senior advisor to Nigeria’s Ministry Responsible For Science. Utah has also held roles with major international technology and finance companies including Google, Palantir and JPMorgan.
